Kamada (TA:KMDA) — Market Cap & Net Worth
Market Cap & Net Worth: Kamada (KMDA)
Kamada (TA:KMDA) has a market capitalization of $377.48 Million (ILA140.80 Billion) as of September 17, 2026. Listed on the TA stock exchange, this Israel-based company holds position #13759 globally and #150 in its home market, demonstrating a -2.24% decrease in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Kamada's stock price ILA2441.00 by its total outstanding shares 57681420 (57.68 Million). Also see how large is Kamada's balance sheet for a full breakdown of the balance sheet.
Kamada Market Cap History: 2015 to 2026
Kamada's market capitalization history from 2015 to 2026. Data shows growth from $252.07 Million to $377.48 Million (4.90% CAGR). Also see Kamada cash conversion from operations for how efficiently the company converts equity into cash flow.
Kamada Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Kamada's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Check KMDA stock price for real-time trading data and today's change.
Latest Price to Sales (P/S) Ratio
2.12x
Kamada's market cap is 2.12 times its annual revenue
Latest Price to Earnings (P/E) Ratio
23.64x
Kamada's market cap is 23.64 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2015 | $252.07 Million | $70.11 Million | -$11.27 Million | 3.60x | N/A |
| 2016 | $325.99 Million | $77.49 Million | -$6.73 Million | 4.21x | N/A |
| 2017 | $255.62 Million | $102.83 Million | $6.90 Million | 2.49x | 37.04x |
| 2018 | $288.87 Million | $114.47 Million | $22.30 Million | 2.52x | 12.96x |
| 2019 | $366.50 Million | $127.19 Million | $22.25 Million | 2.88x | 16.47x |
| 2020 | $319.64 Million | $133.25 Million | $17.14 Million | 2.40x | 18.65x |
| 2021 | $317.79 Million | $103.64 Million | -$2.23 Million | 3.07x | N/A |
| 2022 | $213.10 Million | $129.34 Million | -$2.32 Million | 1.65x | N/A |
| 2023 | $344.39 Million | $142.52 Million | $8.28 Million | 2.42x | 41.57x |
| 2024 | $341.91 Million | $160.95 Million | $14.46 Million | 2.12x | 23.64x |
Competitor Companies of KMDA by Market Capitalization
Companies near Kamada in the global market cap rankings as of September 17, 2026. Review KMDA intangible-adjusted equity ratio to assess the quality of the company's equity after excluding intangible assets.
Key companies related to Kamada by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #518 globally with a market cap of $52.60 Billion USD.
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #631 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #636 globally with a market cap of $43.34 Billion USD.
- Haleon plc (NYSE:HLN): Ranked #672 globally with a market cap of $40.69 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #518 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #631 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €16.00 |
| #636 | GALDERMA GROUP AG | NYSE:GALDY | $43.34 Billion | $37.18 |
| #672 | Haleon plc | NYSE:HLN | $40.69 Billion | $9.24 |
Kamada Historical Marketcap From 2015 to 2026
Between 2015 and today, Kamada's market cap moved from $252.07 Million to $ 377.48 Million, with a yearly change of 4.90%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ILA377.48 Million | +8.01% |
| 2025 | ILA349.49 Million | +2.22% |
| 2024 | ILA341.91 Million | -0.72% |
| 2023 | ILA344.39 Million | +61.61% |
| 2022 | ILA213.10 Million | -32.94% |
| 2021 | ILA317.79 Million | -0.58% |
| 2020 | ILA319.64 Million | -12.78% |
| 2019 | ILA366.50 Million | +26.87% |
| 2018 | ILA288.87 Million | +13.01% |
| 2017 | ILA255.62 Million | -21.58% |
| 2016 | ILA325.99 Million | +29.33% |
| 2015 | ILA252.07 Million | -- |
End of Day Market Cap According to Different Sources
On Sep 16th, 2026 the market cap of Kamada was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $377.48 Million USD |
| MoneyControl | $377.48 Million USD |
| MarketWatch | $377.48 Million USD |
| marketcap.company | $377.48 Million USD |
| Reuters | $377.48 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Kamada
Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmuniza… Read more